



Sequella, Inc.
9610 Medical Center Drive
Rockville, MD 20850
Tele: 301-762-7776
www.sequella.com

NEWS RELEASE

Sequella Presentation at the 2005 Gordon Research Conference on TB Drug Development

ROCKVILLE, MD, August 18, 2005-- Sequella, Inc., a privately held biotechnology company developing products for global infectious disease, presented SQ109 pre-clinical data at the Gordon Research Conference on TB Drug Development. The conference was held at the University of New England in Maine July 3-9, 2005. The presentation contents are available on request.

Dr. Ping Chen, Director of Microbiology for Sequella, presented "**Synergistic killing of *Mycobacterium tuberculosis* by the combination of Rifampin and SQ109, a new TB drug candidate**". The data from these studies demonstrate that SQ109 acts synergistically with rifampin against *M. tuberculosis* and enhances multi-drug therapy in TB mouse models. In addition, SQ109 is effective in treating drug resistant-*M. tuberculosis*. These study results provide support for future clinical trials using SQ109 as a replacement for one or more drugs of the existing first-line TB drug regimen in the WHO-recommended Directly Observed Therapy (DOT). This work was supported by the NIH Challenge Grant program for anti-TB drug development.

About Sequella, Inc.

Sequella, Inc. is developing and commercializing products that address global infectious disease. The company, headquartered in Rockville, MD, is focusing its initial research efforts on therapeutics and diagnostics to address worldwide tuberculosis (TB). For company information, please visit www.sequella.com.

For more information, please contact:

Henrik Wranaker

Corporate Development

Sequella, Inc.

9610 Medical Center Drive, Suite 200

Rockville, MD 20850

301-762-7776; 301-762-7778 (fax)

henrikwranaker@sequella.com